A privately kept company dedicated to bringing new anti-cancer therapies to market.
ACT signs contract to choose novel clinical applicants for just two cancer metabolic programs Advanced Cancer Therapeutics , a privately kept company dedicated to bringing new anti-cancer therapies to market, today announced that this has signed an exclusive agreement to leverage the translational research knowledge of Dr. Jason Chesney, Associate Professor, Department of Medicine at the University of Louisville’s James Graham Dark brown Cancer Center , to identify new medical candidates for the treatment and prevention of cancers against two key cancer metabolic targets. Chesney will work with ACT to further refine and advance the preclinical applicants and backup substances against two exciting and novel malignancy targets that are known as 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 and Choline Kinase , both key cancer rate of metabolism targets recognized by Dr tadalafil .
Upon finding the healthcare physician or facility, the app provides a map of their area and the capability to connect via phone from the iPhone. The intuitively designed app provides members immediate access to thousands of wellness topics also, such as first aid information covering emergencies, bites and stings, minor injuries and poisonings. Users can search wellness information by topic or by particular symptoms with the A.D.A.M. Symptom Navigator, which allows people to search symptoms simply by touching part of the body. With just a tap or a swipe, the Sign Navigator view can be changed for age group and gender, and show relevant symptom results for every. Related StoriesDiabetic retinopathy therapy improvements: an interview with Richard Kirk, CEO of PolyphotonixGenetic carrier screening: an interview with Don Hardison, CEO of Good Start GeneticsReducing medical center readmissions through Transitional Treatment: an interview with Rani Khetarpal Mobile systems are one of the fastest growing regions of healthcare technology today, said Tag Adams, president and ceo at A.D.A.M.